Surgery and postoperative radiotherapy a valid treatment for advanced oropharyngeal carcinoma by Lybak, Stein et al.
HEAD AND NECK
Surgery and postoperative radiotherapy a valid treatment
for advanced oropharyngeal carcinoma
Stein Lybak • Per Gunnar Liavaag •
Odd R. Monge • Jan Olofsson
Received: 8 January 2010/Accepted: 8 July 2010/Published online: 28 August 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Since 1992 we have prospectively included all
head and neck cancer patients in our health region in a
departmental based register. Our hospital takes care of all
head and neck cancer patients in our health region con-
sisting of approximately 1 million people. In 1997, we
evaluated the results of the treatment of oropharyngeal
cancer in the 1992–1997 period. On the basis of this
evaluation, we changed our treatment policy for tonsillar
and base of tongue carcinoma. We ﬁrst changed the
treatment for the lesions with worst prognosis, i.e., those
with T3–T4 carcinomas, from radiotherapy only, to radical
surgery and postoperative radiotherapy. We have since that
time increasingly also operated the smaller oropharyngeal
carcinomas. The 2 years’ overall survival and disease-
speciﬁc survival for all patients diagnosed in the
1992–1997 period was 56 and 63%, respectively. The
results from a similar group of patients in the 6 years’
period from 2000 to 2005, after the change in treatment,
have increased to 83 and 88%. When we looked at the
subgroup of patients in the 2000–2005 period treated with
surgery and postoperative radiotherapy, 45 out of 69
patients (65%) presenting with an oropharyngeal cancer
were ﬁt for operation. With radical surgery and postoper-
ative radiation therapy, the 2 years overall survival is now
91%. The 2-year disease-speciﬁc survival is 96% and the
locoregional control is 98%. This is a marked improvement
as compared to radiotherapy alone and deﬁnitely compet-
itive with modern radiochemotherapy.
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Introduction
The treatment of oropharyngeal cancer varies widely
between different institutions. The choice of treatment is
based on local and to some extent regional traditions and
availability of resources. The dominating treatments have
been radiotherapy as a single treatment or a combination of
surgery and radiotherapy. Lately, chemotherapy concomi-
tant to radiotherapy or as adjuvant therapy has increased in
use [1, 2].
When looking into the overall results of the treatment
of oropharyngeal cancer, few studies show the overall,
population based patient material. Most studies show only
the results of the treated groups and give little or no
information of the size and character of the non-included
patient group. This is a bias in most studies and makes the
overall survival (OS) for the whole oropharyngeal patient
group impossible to validate and comparison of studies
inaccurate.
One of the largest studies of overall results is the study
of tongue base cancer by Zhen et al. [3] of more than
16,000 patients from the National Cancer Data Bank. They
found a 2 years’ OS of 48.7% and a 5 years’ OS of 27.8%.
Other results from studies including population-based
patient material are: The Dutch multi-institutional study of
tonsillar cancer by Mak-Kregar et al. [4] with a 5 years’ OS
of 32%, the Danish study of oropharyngeal cancers by
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study on oropharyngeal cancer by Makitie et al. [6] with a
3 years’ OS of 58% and a 5 years OS of 45%, and the
study from Oslo by Hannisdal et al. [7] of tonsillar cancer
with a 5 years’ OS of 34% (Table 1). We have not found
any population-based study based on modern chemo-
radiation treatment.
Many studies have been designed to compare the suc-
cess of radiotherapy to that of combination therapy with
surgery and radiotherapy. The large multicenter study of
Parson et al. [8] collecting data from a large number of
studies on tonsillar and tongue base cancers from USA and
Canada, with about 6,400 patients, did not show any sig-
niﬁcant difference in outcome between the two treatment
modalities. Mendenhall et al. [9] came to the same con-
clusion in their article based on 400 patients treated with
radiotherapy only, or in combination with neck dissection.
Other studies [4, 10] have found combination treatment
better than radiotherapy as a single treatment.
A cancer register including all patients in a well-deﬁned
region gives us the chance to follow and evaluate the
longitudinal ﬂow of patients. The patient material in any
time period in such a longitudinal follow up will not
change to any large extent. By introducing a change in
treatment, deﬁned in time, we can monitor any change in
outcome caused by such a change. This is the basis of this
study.
Patients and methods
Since the ﬁrst of January 1992 all patients seen with a new
diagnosis of cancer in the Department of Otolaryngology/
Head & Neck Surgery have been registered in a hospital-
based cancer register (HBCR). The basis of the HBCR is
the Western Health Care Region of Norway (WHCR). The
region today includes approximately one million inhabit-
ants. All patients evaluated and treated in our hospital are
seen in a joint oncology meeting with staff from the
departments of Otolaryngology/Head & Neck Surgery and
Oncology, and when required, also from other departments
such as Plastic Surgery and Oral Surgery. This meeting
also includes all patients with incurable cancer and all
patients where no treatment is provided. Therefore, the
HBCR includes very close to 100% of all new head and
neck cancer patients within our well-deﬁned geographical
area. All patients from outside the WHCR treated in our
hospital are omitted from our study. The patient referral
base is therefore identical in the two periods.
The HBCR is based on a Filemaker Pro data ﬁle. The
data base is registered and approved by the Norwegian
Social Science Data Services.
The patients are registered with name, date of birth, date
of diagnosis, ICD classiﬁcation, TNM classiﬁcation, and
treatment. All new cancer events such as recurrences, new
treatments, new cancers, and deaths are continuously
recorded.
The present study is based on the data of oropharyngeal
cancer patients in two deﬁned periods. The ﬁrst period
includes all patients from 1992 up to the end of 1997 and
the second period includes all patients from 2000 up to the
end of 2005.
The ﬁrst evaluation based on the data from the HBCR
was done in 1997–1998 with focus on tongue base and
tonsillar cancers. This treatment group therefore includes
all patients registered in the 6-year period 1992–1997.
To improve the outcome for patients with advanced
oropharyngeal cancers, we decided to change our treatment
policy from radiation only, to radical surgery and postop-
erative radiation therapy. We always start radical surgery
with a tracheotomy. This removes the tubing from the
operating ﬁeld, and secures the airway in the postoperative
period. It also helps in the protection of the airway when
the patient starts oral feeding. A neck dissection on the
same side as the primary tumor is standard and a bilateral
neck dissection when the primary tumor goes to the mid-
line or to the contralateral side. We perform an open
mandibular split in the area of teeth 3–4 with simultaneous
splitting of the lip. The splitting and subsequent lateral
displacement of the mandible give us a very good control
over the area between the primary tumor and the neck area
and with macroscopical surgical margins when resecting
the primary tumor. We ﬁnd this approach also of great
beneﬁt in the reconstruction phase of the surgery. The
majority of patients have been reconstructed with a free
radial forearm ﬂap. All surgeries were performed by the
two senior head and neck surgeons at the department and a
microvascular team.
The second phase of the study is based on the changes
done after the evaluation of the ﬁrst phase (1992–1997).
This part of the study includes all patients registered in the
period 2000–2005. We have omitted the patients in the
1998–1999 period since we did not have the new treatment
policy fully implemented in this intermediate period. Since
Table 1 Studies based on overall survival in squamous cell carci-
noma of the oropharynx
Site of cancer 2 years
OS (%)
3 years
OS (%)
5 years
OS (%)
Zhen et al. [3] Tongue base 48.7 27.8
Mak-Kregar et al. [4] Tonsil 32
Johansen et al. [5] Oropharynx 31
Makitie et al. [6] Oropharynx 58 45
Hannisdal et al. [7] Tonsil 34
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1232000, all patients diagnosed with a tonsillar or tongue base
cancer have been recommended and offered surgery and
postoperative radiation treatment if the tumor and the
patient have been found suitable for such treatment.
All data are shown as crude 2 years’ overall survival and
2 years’ disease-speciﬁc survival (DSS), calculated from
the time of diagnosis. The analysis of results as early as
2 years after treatment is valid due to the fact that almost
all recurrences occur within this short time interval. In a
total of 142 patients from 1992 to 2005, we have had only
two recurrences occurring after the 2-year post-treatment
period. One was a regional recurrence on the contralateral
side at 26 months (treated and cured) and one was a pos-
sible recurrence at 44 months (could have been a new
primary cancer not far from the location of the ﬁrst cancer).
Hinerman et al. [11] in their study of 134 patients also
found only one patient with a cancer recurrence occurring
later than 2 years after treatment (77 months after treat-
ment!). Harrison et al. [12] in their study of 68 patients had
no local failures after 16 months and one regional failure
after 2 years. Based on these ﬁgures, the chance of a
locoregional recurrence for a patient surviving 2 years
without such a recurrence, is\2%.
Radiotherapy has been given as external beam radiation
with a linear accelerator in one course treatment. We used
one dose of 2 Gy/day, 5 doses/week as standard treatment.
Radiotherapy dose was 70 Gy to all macroscopic tumors
and to postoperative areas with marginal histological
borders. No major change in radiotherapy treatment policy
has been made in the study period except for the two
younger inoperable patients who in recent years have been
treated with concomitant chemo-radiation treatment.
Intensity-modulated radiotherapy (IMRT) has been used on
a few selected patients in the later years.
Two and ﬁve years OS were calculated by using com-
puterized software package (SPSS).
Patient characteristics are shown in Table 2. We diag-
nosed 45 patients in the 1992–1997 period and 69 patients
in the 2000–2005 period. Median age was 59 years; 7.5
patients per year were included in the ﬁrst period and 11.5
patients per year in the second period. At the time of
diagnosis the T stages were as follows: T1: n = 22 (19%);
T2: n = 36 (32%); T3: n = 27 (24%); T4: n = 29 (25%).
Stage distribution at the time of diagnosis were: I: n = 4
(3.5%); II: n = 9 (8%); III: n = 18 (16%); IV: n = 83
(73%). Tongue base was dominated by stage IV cancers
(83%).
Neck metastases at the time of diagnosis were detected
in 79% of the patients (76% of the patients in the
1992–1997 period and 81% in the 2000–2005 period). The
patients with T3 ? T4 tumors made up 49% of the patient
material (40% in the ﬁrst period and 54% in the second
period). Stage III ? Stage IV made up 89% of the patient
material (84% in the ﬁrst period and 91% in the second
period).
Eight (7%) patients were not treated or did not survive
the treatment period (three patients started but did not
ﬁnish radiotherapy treatment). All other patients received
treatment with curative intent (i.e. no treatment group
received palliative treatment).
Results
A total of 114 patients with squamous cell carcinoma of
the lateral pharyngeal wall and tongue base have been
diagnosed in our region in these two periods; 85 patients
had tonsillar cancer and 29 tongue base cancer; 85 were
men and 29 were women with a mean age of 59 years.
In the 1992–1997 period, 45 patients ﬁtting the inclusion
criteria were diagnosed; 4 patients were not treated; 27
(60%) patients received radiotherapy as single modality
treatment; 14 (31%) patients were operated and given
postoperative radiotherapy. Almost all the operations in
this period consisted of tonsillectomy and neck dissection
(four patients were operated with more radical surgery).
Two years from the time of diagnosis no patients in the
non-treated group were alive; 15 (56%) in the radiother-
apy only group; 10 (71%) in the group treated with
operation and postoperative radiotherapy (Fig. 1). Two
years’ OS and DSS for the entire group were 56 and 63%,
respectively. Two years’ OS and DSS for the treated
patients were 60 and 66%. Five years’ OS and DSS were
49 and 59% (Table 3). The difference between the 2 and
5 years’ OS was due to one cancer death and two non-
cancer deaths.
In the further analysis of the radiotherapy only group,
we divided the group into two treatment groups: T1 ? T2
and T3 ? T4. The T1 ? T2 group consisted of 15 patients,
11 (73%) of whom survived 2 years. The T3 ? T4 group
consisted of 12 patients, 4 (33%) of whom survived 2 years
(Fig. 2).
Table 2 Patient characteristics
Period
1995–1997
Period
2000–2005
Patients included 45 69
Average age (years) 57.6 60.6
Proportion females (%) 24 26
Patients per year 7.5 11.5
Proportion tongue base cancers (%) 18 30
Node positive patients (pretreatment) (%) 76 81
T3 ? T4 (%) 40 54
Stage III ? IV (%) 84 91
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we decided to operate and give postoperative radiotherapy
to patients with T3 ? T4 cancer of the lateral oropharyn-
geal wall and base of tongue. We have lately also operated
on T1 and T2 tumors.
In the 2000–2005 period, 69 patients ﬁtting the inclusion
criteria were diagnosed. Four patients were not treated; 20
(29%) patients received radiotherapy treatment as single
modality treatment; 45 (65%) patients were operated and
given postoperative radiotherapy. Two years from the time
of diagnosis no patients in the non-treated group were
alive; 16 (80%) patients in the radiotherapy group and 41
(91%) patients in the group treated with operation and
postoperative radiotherapy were alive (Fig. 3). Two years’
OS and DSS for the entire group including the non-treated
patients, were 83 and 88%. Two years’ OS and DSS for the
treated patients were 88 and 93% (Table 3). In the later
study period, we have operated a total of 45 patients
(31 with radical operations) (Fig. 4). The stages of the rad-
ically operated patients were as follows: II: 2; III: 6; IV: 23.
We have surgically removed and given postoperative
radiotherapy to the local tumor in 40 patients (31 as part of
radical surgery and in 9 patients with T1–T2 cancers as a
transoral excision in patients with tonsillar cancers). Only
one of these patients experienced a local recurrence. This
patient had a tonsillar tumor with extensive growth into the
retro-molar area (C09.1/T3N2b).
Forty-ﬁve patients were treated with neck dissection and
postoperative radiotherapy (31 as part of radical surgery, in
9 patients with T1–T2 cancers as a transoral excision in
patients with tonsillar cancers and in 5 patients with T1–T2
cancers were only biopsy were done locally). No recur-
rences have occurred in the treated necks. One patient
experienced a recurrence in the contralateral untreated
neck. This patient was treated with surgery and postoper-
ative radiotherapy and is cured. This gives us a 2 years’
DSS and locoregional control in the surgically treated
group of 96 and 98%, respectively.
Two of the 45 operated patients have had a distal
recurrence. Both these patients had N2b disease, with
four and ﬁve positive glands respectively, and both had
extranodal tumor growth. This gives us a 4 years’ disease-
speciﬁc survival in the combined treatment group of 96%.
(One patient with bone metastasis is still alive more than
55 months from date of diagnosis. No histological conﬁr-
mation has conﬁrmed the nature of these lesions).
Kaplan–Meier calculation of 5 years survival for the
entire patient population in this period is 67% (Fig. 5). Log
Rank (Mantel–Cox) overall comparison for the two study
periods is p\0.001.
Discussion
In 1997, we evaluated the results of the treatment of
oropharyngeal cancer in the 1992–1997 period. On the
basis of this evaluation, we changed our treatment policy
for tonsillar and base of tongue carcinoma. We ﬁrst
changed the treatment for the lesions with worst prognosis,
i.e., those with T3–T4 carcinomas, from radiotherapy only,
to radical surgery and postoperative radiotherapy. We have
since that time increasingly also operated the smaller
oropharyngeal carcinomas. The 2 years’ overall survival
and disease-speciﬁc survival for all patients diagnosed in
the 1992–1997 period were 56 and 63%. The result from a
similar group of patients in the 6 years’ period from 2000
to 2005, after the change in treatment, is increased to 83
and 88%.
No. of patients No. of patients alive after 2 years
14 Surgery + radiotherapy (31%) 10 (71%)
45 27
4 Not treated
Radiotherapy (60%) 15
0
(56%) 56%
(92 – 97)
Fig. 1 Two years overall
survival for the whole patient
material in the 1992–1997
period
Table 3 Two years overall and disease spesiﬁc survival
Overall
survival (%)
Disease spesiﬁc
survival (%)
1992–1997 All patients 56 63
1992–1997 Treated patients 60 66
2000–2005 All patients 83 88
2000–2005 Treated patients 88 93
T 1+2 15 11 (73%)
No.of patients No. of patients alive after 2 years
Radiotherapy only
27
T 3+4 12 4 (33%)
Fig. 2 Results from the group of patients treated with radiotherapy
only in the 1992–1997 period
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123When we look at the subgroup of patients in the
2000–2005 period treated with surgery and postoperative
radiotherapy, we found that two out of three patients
presenting with an oropharyngeal cancer were ﬁt for
operation. With radical surgery and postoperative radio-
therapy, the 2 years’ overall survival is now 91%. The
2-year disease-speciﬁc survival is 96% and the locore-
gional control is 98%.
The rise in number of patients with oropharyngeal can-
cer per year, here shown in our population, is in accordance
with the reports by others [5, 13, 14]. Hammarstedt et al.
[13] found a parallell rise in HPV positive tumors with
time, based on re-evaluation of the histopathology, indi-
cating a probable cause for the sharp rise in incidence.
The group of non-treated patients in our study is 7%. All
patients in this group were dead within 6 months except one
patient who lived 13 months after date of diagnosis. There
are very few studies in the literature with control over the
non-treated group in the patient material. In the few studies
where this has been documented, we ﬁnd a surprisingly
large difference in the size of this group, from the Danish
study [5] where only 6% of the patients did not receive
curative intended treatment, to the Dutch study [4] where
22% of the patients did not receive curative intended treat-
ment. By increasing the non-treatment group, the danger,
from a clinical point of view, is that the overall survival will
decrease (and the result in the treated group will theoreti-
cally go up, which is of no clinical importance).
Our results in the 1992–1997 period compare favorably
with the results from other studies [3–6, 8, 13]. We found,
never the less, T3–T4 cancers of the lateral wall of the
oropharynx and tongue base had an unacceptable mortality
rate. Up to this point, almost all operations in our hospital
had been a combination of neck dissection and a tonsil-
lectomy. The decision to operate the T3–T4 oropharyngeal
cancers implied that many patients would be treated with
more extensive radical surgery.
Since 2000 we have recommended operative treatment,
if possible to all patients with cancer of the base of tongue
or lateral pharyngeal wall. Patients with T3–T4 tumors and
larger T2 tumors have been recommended radical surgery.
T1 and smaller T2 tumors have been treated with transoral
extirpation of tumors with free margins and a neck
dissection. All patients were informed about the different
possibilities of treatment (operation and postoperative
radiotherapy, radiotherapy only or chemo-radiotherapy)
and the advantages and disadvantages of the different
alternatives. We always try to involve the patients to
actively take part in the selection of treatment. The clinical
contraindications we found to surgical treatment were
almost always based upon poor general health. The only
technical contraindication we found to surgery was cancer
surrounding the internal carotid artery in two patients.
In general, patients found unﬁt for surgery due to poor
generalhealthwerealsofoundunﬁtforchemo-radiotherapy.
In the 2000–2005 study period, 65% of the patients
receiving treatment were treated with surgery and postop-
erative radiotherapy, and most of these surgical procedures
were major radical surgery (31/45). The results from the
later period showed an increase in 2 years overall survival
forthesurgicalgroupcomparedwiththeﬁrstperiodfrom71
to 91%. This increase, combined with the fact that we
moved patients from the worst prognostic group (T3–T4
treated with radiotherapy only) to the surgery plus radio-
therapy group, gave the rise in 2 years OS for the entire
groupfrom56to83%,andforthetreatedpatientsfrom60to
88% (Table 3). The increase in survival in the group treated
with radiotherapy only is most likely caused by the fact that
4 Sd i h ( 6 % ) 41 (91%)
69
45
20
urgery + ra ot erapy  5
Radiotherapy (29%)
41
16
(91%)
(80%) 83%
4 Not treated 0
00 –05
Fig. 3 Two years overall
survival for the whole patient
material in the 2000–2005
period
Fig. 4 Overall survival for all patients diagnosed with tongue base
and lateral wall oropharyngeal cancer in the 1992–1995 and
2000–2005 period
Eur Arch Otorhinolaryngol (2011) 268:449–456 453
123themostadvancedtumorshavebeentransferredtothegroup
treated with operation and postoperative radiotherapy.
When we compare the patient material from the ﬁrst and
second study periods, we ﬁnd that the TNM classiﬁcation
has become more advanced. We believe this is mainly the
result of increased use of MRI of the oropharynx and
ultrasound of the neck in the second study period. The
importance of this increased diagnostic capability is that it
gives us a better chance to tailor the treatment to the
individual patient’s disease both in terms of surgical
resections and radiotherapy planning.
Functional results in the radically operated group of
patients have not been systematically evaluated. However,
only one patient ended up with a permanent feeding tube,
all other patients are orally fed. Speech is satisfactory in all
patients, but some nasal sound is persistent in the patients
where large parts of the soft palate have been removed. The
most common complaint from the patients is dryness of the
mouth and pharynx. Data on functional results and quality
of life are presently investigated and will be reported.
Similar results are reported by transoral laser micro-
surgery followed by radiotherapy or chemo-radiotherapy
with 94 and 88% overall survival at 2 and 5 years,
respectively [15].
So called organ preservation techniques using induction
plus concurrent chemo-radiotherapy (carboplatin and
paclitaxel) for advanced resectable oropharyngeal carcino-
mas yielded a 3 year actuarial locoregional control of 82%
[16]. Finnegan et al. [17] using neoadjuvant chemotherapy
followed by concurrent hyperfractionated radiation therapy
and sensitizing chemotherapy for locally advanced T3 or T4
oropharyngeal carcinomas in 23 patients reported an abso-
lute 2 and 5 years survival rate of 71 and 55%, respectively.
The use of intensity-modulated radiation treatment
(IMRT) may improve the control rate and minimize
toxicity and even better results may be achieved by using
IMRT together with chemotherapeutic agents [18].
Huang et al. [19] using intensity-modulated chemo-
radiotherapy for treatment of stages III and IV oropha-
ryngeal carcinoma yielded a 3 year overall survival of
83%. Similar results are reported with concurrent chemo-
therapy and intensity-modulated radiation therapy, but
including a mixed oropharyngeal and laryngeal material
and yielding a 3 year overall survival rate of 81.2% [20].
There are also other good results reported by primary
surgery followed by radiotherapy. Ro ¨o ¨sli et al. [21]
reported a 5 year overall survival of 57.9% for their entire
cohort of 427 consecutive patients with oropharyngeal
squamous cell carcinoma treated from 1990 to 2006; 102
patients were treated by surgery alone and 159 with adju-
vant chemo-radiotherapy. The 5 year overall survival for
surgery alone was 70.3% and for surgery with radiation
66.6%. Their conclusion was that surgery alone for early
oropharyngeal carcinomas and surgery followed by radia-
tion for advanced oropharyngeal carcinomas remain a
valuable treatment option but they consider primary chemo-
radiotherapy as a strong alternative for those patients who
are not candidates for functional preserving surgery.
Cohan et al. [22] state that ‘‘Advanced SCCs of the
oropharynx (T3–T4, nodally aggressive, or both) require
multimodal approaches consisting of either surgery along
with adjuvant radiotherapy or concurrent chemo-radio-
therapy along with salvage surgery (as necessary)’’.
Jones et al. [23] state that for locally advanced carci-
nomas of the oropharynx primary surgery with immediate
microvascular reconstruction followed by radical radio-
therapy would be the treatment of choice. They seem,
however, not especially optimistic as they at the same time
state that the treatment with curative intent for advanced
disease is not any better than palliation alone in terms of
survival at 5 years. They also ﬁnd that surgery and radio-
therapy are equivalent in controlling the disease.
Low survival rates have been reported in a fairly large
series of 361 patients treated in 1990–2001 in Brazil
yielding a 5 year overall survival rate of only 17.6% [24].
These patients were treated by primary radiotherapy alone
or with chemotherapy. They found that age, Zubrod scale,
weight loss, involvement of the adjacent soft tissue area
and bone, lymph node mobility, clinical stage, and radio-
therapy dose were all prognostic factors.
R/ 2 Cancerdeaths
31
Recurrences / 2 years
2
Cancerdeaths
1 4
C09.1 (T3N2b) Local rec(12mnd)
(dead:15)
C09.9 (T3N2b) Met generalized (12 mnd)
()
One patient treated and 
cured with operation and 
postoperative
radiotherapy for a 
it h
(dead:20 mnd)
C09.9 (T2N2b) Met generalized (22 mnd) 
(Still alive 55 mnd)
recurrence in the
contralateral neck
Fig. 5 Results of the radically
operated patients with
postoperative radiotherapy
454 Eur Arch Otorhinolaryngol (2011) 268:449–456
123Haigentz et al. [25] reviewing the current trends in the
initial management of oropharyngeal cancer state that the
true role of chemotherapy in oropharyngeal cancer requires
further research. Anyhow most authors today recommend
chemo-radiotherapy for advanced oropharyngeal carcino-
mas due to better quality of life despite that prospective
randomized studies are missing [26].
Concluding remarks
The treatment of oropharyngeal cancer in our institution
has become more individualized. We favor a combination
of surgery with postoperative radiotherapy as the treatment
of choice for most oropharyngeal patients, if the patients
are motivated and medically ﬁt for such treatment. It must
be stressed that our improved results are based on a com-
bined treatment. Improvements in both surgery, radiother-
apy and diagnostic work-up are all important factors for the
improvements in outcome that we have seen. For patients
not treated with operation, we have introduced chemo-
radiotherapy treatment in the later years. All younger
patients, found technically inoperable, are offered such
combined treatment, but this is a very small group of
patients. Only two patients were found inoperable for
technical reasons (both had tumors surrounding the internal
carotid artery). For all other non-operated patients, the
reasons were inoperability based on poor general health,
and this is a patient population generally not ﬁt for chemo-
radiotherapy treatment either.
We have shown survival ﬁgures that are comparable or
even better than modern chemo-radiotherapy. The func-
tional results are good with most persons returning to work
and only one of the patients treated with surgery plus
radiotherapy has a permanent feeding tube (PEG). The
functional results will be further elaborated on in a
subsequent review.
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